Drug Profile
Research programme: sestrin modulators - Quark Pharmaceuticals
Alternative Names: Sestrin modulators research programme - Quark PharmaceuticalsLatest Information Update: 31 Aug 2010
Price :
$50
*
At a glance
- Originator Quark Biotech
- Developer Quark Pharmaceuticals
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders
Most Recent Events
- 21 Jun 2004 Preclinical trials in Ischaemic heart disorders in USA (unspecified route)